



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an independent licensee of the Blue Cross and Blue Shield Association

Medical Policy Microwave Tumor Ablation

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 912

BCBSA Reference Number: 7.01.133

NCD/LCD: NA

Related Policies

- Cryosurgical Ablation of Primary or Metastatic Liver Tumors, [#633](#)
- Radiofrequency Ablation of Primary or Metastatic Liver Tumors, [#286](#)
- Cryosurgical Ablation of Miscellaneous Solid Tumors Other Than Liver, Prostate, or Dermatologic Tumors, [#260](#)
- Radiofrequency Ablation of Miscellaneous Solid Tumors Excluding Liver Tumors, [#259](#)
- Intraoperative Radiation Therapy, [#612](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

Microwave ablation of primary and metastatic tumors is considered [INVESTIGATIONAL](#).

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	This is not a covered service.
Commercial PPO and Indemnity	This is not a covered service.
Medicare HMO Blue SM	This is not a covered service.
Medicare PPO Blue SM	This is not a covered service.

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

CPT Codes

There is no specific CPT code for microwave ablation for most primary and metastatic tumors.

DESCRIPTION

MICROWAVE ABLATION

Microwave ablation (MWA) uses microwave energy to induce an ultra-high speed, 915 MHz or 2.450 MHz (2.45 GHz), alternating electric field, which causes water molecule rotation and creates heat. This results in thermal coagulation and localized tissue necrosis. In MWA, a single microwave antenna or multiple antennas connected to a generator are inserted directly into the tumor or tissue to be ablated; energy from the antennas generates friction and heat. The local heat coagulates the tissue adjacent to the probe, resulting in a small, 2- to 3-cm elliptical area (5×3 cm) of tissue ablation. In tumors greater than 2 cm in diameter, 2 to 3 antennas may be used simultaneously to increase the targeted area of MWA and shorten the operative time. Multiple antennas may also be used simultaneously to ablate multiple tumors. Tissue ablation occurs quickly, within 1 minute after a pulse of energy, and multiple pulses may be delivered within a treatment session, depending on tumor size. The cells killed by MWA are typically not removed but are gradually replaced by fibrosis and scar tissue. If there is a local recurrence, it occurs at the margins. Treatment may be repeated as needed. MWA may be used for the following purposes: (1) to control local tumor growth and prevent recurrence; (2) to palliate symptoms; and (3) to prolong survival.

MWA is similar to radiofrequency (RFA) and cryosurgical ablation. However, MWA has potential advantages over RFA and cryosurgical ablation. In MWA, the heating process is active, which produces higher temperatures than the passive heating of RFA and should allow for more complete thermal ablation in less time. The higher temperatures reached with MWA (>100°C) can overcome the "heat sink" effect in which tissue cooling occurs from nearby blood flow in large vessels, potentially resulting in incomplete tumor ablation. MWA does not rely on the conduction of electricity for heating and, therefore, does not flow electrical current through patients and does not require grounding pads, because there is no risk of skin burns. Additionally, MWA does not produce electric noise, which allows ultrasound guidance during the procedure without interference, unlike RFA. Finally, MWA can take less time than RFA, because multiple antennas can be used simultaneously.

Adverse Events

Complications from MWA are usually mild and may include pain and fever. Other complications associated with MWA include those caused by heat damage to normal tissue adjacent to the tumor (eg, intestinal damage during MWA of the kidney or liver), structural damage along the probe track (eg, pneumothorax as a consequence of procedures on the lung), liver enzyme elevation, liver abscess, ascites, pleural effusion, diaphragm injury, or secondary tumors if cells seed during probe removal. MWA should be avoided in pregnant women because potential risks to the patient and/or fetus have not been established, and in patients with implanted electronic devices (eg, implantable pacemakers) that may be adversely affected by microwave power output.

Applications

MWA was first used percutaneously in 1986 as an adjunct to liver biopsy. Since then, MWA has been used to ablate tumors and tissue to treat many conditions including hepatocellular carcinoma, breast cancer, colorectal cancer metastatic to the liver, renal cell carcinoma, renal hamartoma, adrenal malignant carcinoma, non-small-cell lung cancer, intrahepatic primary cholangiocarcinoma, secondary splenomegaly and hypersplenism, abdominal tumors, and other tumors not amenable to resection. Well-established local or systemic treatment alternatives are available for each of these malignancies. The potential advantages of MWA for these cancers include improved local control and other advantages

common to any minimally invasive procedure (eg, preserving normal organ tissue, decreasing morbidity, shortening length of hospitalization). MWA also has been investigated as a treatment for unresectable hepatic tumors, as both primary and palliative treatment, and as a bridge to liver transplant. In the latter setting, MWA is being assessed to determine whether it can reduce the incidence of tumor progression while awaiting transplantation and thus maintain a patient’s candidacy while awaiting a liver transplant.

Summary

Microwave ablation (MWA) is a technique to destroy tumors and soft tissue using microwave energy to create thermal coagulation and localized tissue necrosis. MWA is used to treat tumors not amenable to resection and to treat patients ineligible for surgery due to age, comorbidities, or poor general health. MWA may be performed as an open procedure, laparoscopically, percutaneously, or thoracoscopically under image guidance (eg, ultrasound, computed tomography, magnetic resonance imaging) with sedation, or local or general anesthesia. This technique is also referred to as microwave coagulation therapy.

For individuals who have an unresectable primary or metastatic tumor (eg, breast, hepatic [primary or metastatic], pulmonary, renal) who receive MWA, the evidence includes case series, observational studies, cohort studies, randomized controlled trials, and systematic reviews. Relevant outcomes are overall survival, disease-specific survival, symptoms, quality of life, and treatment-related mortality and morbidity. Available studies have shown that MWA results in a wide range of complete tissue ablation (50%-100%) depending on tumor size, with complete ablation common and nearing 100% with smaller tumors (eg, ≤3 cm). Tumor recurrence rates at ablated sites are very low. However, tumor recurrence at nonablated sites is common and may correlate with disease state (eg, in hepatocellular carcinoma). Intraoperative and postoperative minor and major complications are low, especially when tumors are smaller and accessible. Patient selection criteria and rationale for using MWA instead of other established techniques (eg, surgical resection, radiofrequency ablation) are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

Policy History

Date	Action
10/2018	BCBSA National medical policy review. Description, summary and references updated. Policy statement unchanged.
1/2018	Clarified coding information.
10/2017	New references added from BCBSA National medical policy.
4/2016	New references added from BCBSA National medical policy.
12/2014	New references added from BCBSA National medical policy.
1/2014	New references added from BCBSA National medical policy.
4/2013	New references from BCBSA National medical policy.
2/2013	New policy describing non-coverage.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Zhao Z, Wu F. Minimally-invasive thermal ablation of early-stage breast cancer: a systematic review. *Eur J Surg Oncol.* Dec 2010;36(12):1149-1155. PMID 20889281
2. Zhou W, Zha X, Liu X, et al. US-guided percutaneous microwave coagulation of small breast cancers: a clinical study. *Radiology.* May 2012;263(2):364-373. PMID 22438362

3. Chinnaratha MA, Chuang MY, Fraser RJ, et al. Percutaneous thermal ablation for primary hepatocellular carcinoma: A systematic review and meta-analysis. *J Gastroenterol Hepatol*. Feb 2016;31(2):294-301. PMID 26114968
4. Bertot LC, Sato M, Tateishi R, et al. Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review. *Eur Radiol*. Dec 2011;21(12):2584-2596. PMID 21858539
5. Ong SL, Gravante G, Metcalfe MS, et al. Efficacy and safety of microwave ablation for primary and secondary liver malignancies: a systematic review. *Eur J Gastroenterol Hepatol*. Jun 2009;21(6):599-605. PMID 19282763
6. Taniai N, Yoshida H, Mamada Y, et al. Is intraoperative adjuvant therapy effective for satellite lesions in patients undergoing reduction surgery for advanced hepatocellular carcinoma? *Hepatogastroenterology*. Mar-Apr 2006;53(68):258-261. PMID 16608035
7. Shibata T, Iimuro Y, Yamamoto Y, et al. Small hepatocellular carcinoma: comparison of radiofrequency ablation and percutaneous microwave coagulation therapy. *Radiology*. May 2002;223(2):331-337. PMID 11997534
8. Abdelaziz AO, Nabeel MM, Elbaz TM, et al. Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis. *Scand J Gastroenterol*. Apr 2015;50(4):479-484. PMID 25592058
9. Vogl TJ, Farshid P, Naguib NN, et al. Ablation therapy of hepatocellular carcinoma: a comparative study between radiofrequency and microwave ablation. *Abdom Imaging*. Aug 2015;40(6):1829-1837. PMID 25601438
10. Ding J, Jing X, Liu J, et al. Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma. *Eur J Radiol*. Sep 2013;82(9):1379-1384. PMID 23726122
11. Ding J, Jing X, Liu J, et al. Complications of thermal ablation of hepatic tumours: comparison of radiofrequency and microwave ablative techniques. *Clin Radiol*. Jun 2013;68(6):608-615. PMID 23399463
12. Takami Y, Ryu T, Wada Y, et al. Evaluation of intraoperative microwave coagulo-necrotic therapy (MCN) for hepatocellular carcinoma: a single center experience of 719 consecutive cases. *J Hepatobiliary Pancreat Sci*. Mar 2013;20(3):332-341. PMID 22710886
13. Yu J, Liang P, Yu XL, et al. Needle track seeding after percutaneous microwave ablation of malignant liver tumors under ultrasound guidance: analysis of 14-year experience with 1462 patients at a single center. *Eur J Radiol*. Oct 2012;81(10):2495-2499. PMID 22137097
14. Zhou P, Liang P, Dong B, et al. Long-term results of a phase II clinical trial of superantigen therapy with staphylococcal enterotoxin C after microwave ablation in hepatocellular carcinoma. *Int J Hyperthermia*. Dec 2011;27(2):132-139. PMID 21117923
15. Zhou P, Liang P, Yu X, et al. Percutaneous microwave ablation of liver cancer adjacent to the gastrointestinal tract. *J Gastrointest Surg*. Feb 2009;13(2):318-324. PMID 18825464
16. Lu MD, Xu HX, Xie XY, et al. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. *J Gastroenterol*. Nov 2005;40(11):1054-1060. PMID 16322950
17. Loveman E, Jones J, Clegg AJ, et al. The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation. *Health Technol Assess*. Jan 2014;18(7):vii-viii, 1-283. PMID 24484609
18. Bala MM, Riemsma RP, Wolff R, et al. Microwave coagulation for liver metastases. *Cochrane Database Syst Rev*. Oct 13 2013;10(10):CD010163. PMID 24122576
19. Pathak S, Jones R, Tang JM, et al. Ablative therapies for colorectal liver metastases: a systematic review. *Colorectal Dis*. Sep 2011;13(9):e252-265. PMID 21689362
20. Shibata T, Niinobu T, Ogata N, et al. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. *Cancer*. Jul 15 2000;89(2):276-284. PMID 10918156
21. Liu Y, Li S, Wan X, et al. Efficacy and safety of thermal ablation in patients with liver metastases. *Eur J Gastroenterol Hepatol*. Apr 2013;25(4):442-446. PMID 23470267
22. Lorentzen T, Skjoldbye BO, Nolsoe CP. Microwave ablation of liver metastases guided by contrast-enhanced ultrasound: experience with 125 metastases in 39 patients. *Ultraschall Med*. Oct 2011;32(5):492-496. PMID 21259183

23. Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. *Ann Surg Oncol*. Jan 2010;17(1):171-178. PMID 19707829
24. Acksteiner C, Steinke K. Percutaneous microwave ablation for early-stage non-small cell lung cancer (NSCLC) in the elderly: a promising outlook. *J Med Imaging Radiat Oncol*. Feb 2015;59(1):82-90. PMID 25335916
25. Sun YH, Song PY, Guo Y, et al. Computed tomography-guided percutaneous microwave ablation therapy for lung cancer. *Genet Mol Res*. May 11 2015;14(2):4858-4864. PMID 25966260
26. Belfiore G, Ronza F, Belfiore MP, et al. Patients' survival in lung malignancies treated by microwave ablation: our experience on 56 patients. *Eur J Radiol*. Jan 2013;82(1):177-181. PMID 23099201
27. Lu Q, Cao W, Huang L, et al. CT-guided percutaneous microwave ablation of pulmonary malignancies: Results in 69 cases. *World J Surg Oncol*. May 07 2012;10:80. PMID 22564777
28. Vogl TJ, Naguib NN, Gruber-Rouh T, et al. Microwave ablation therapy: clinical utility in treatment of pulmonary metastases. *Radiology*. Nov 2011;261(2):643-651. PMID 22012906
29. Katsanos K, Mailli L, Krokidis M, et al. Systematic review and meta-analysis of thermal ablation versus surgical nephrectomy for small renal tumours. *Cardiovasc Intervent Radiol*. Apr 2014;37(2):427-437. PMID 24482030
30. Guan W, Bai J, Liu J, et al. Microwave ablation versus partial nephrectomy for small renal tumors: intermediate-term results. *J Surg Oncol*. Sep 1 2012;106(3):316-321. PMID 22488716
31. Martin J, Athreya S. Meta-analysis of cryoablation versus microwave ablation for small renal masses: is there a difference in outcome? *Diagn Interv Radiol*. Nov-Dec 2013;19(6):501-507. PMID 24084196
32. Yu J, Liang P, Yu XL, et al. US-guided percutaneous microwave ablation of renal cell carcinoma: intermediate-term results. *Radiology*. Jun 2012;263(3):900-908. PMID 22495684
33. Muto G, Castelli E, Migliari R, et al. Laparoscopic microwave ablation and enucleation of small renal masses: preliminary experience. *Eur Urol*. Jul 2011;60(1):173-176. PMID 21531501
34. Bai J, Hu Z, Guan W, et al. Initial experience with retroperitoneoscopic microwave ablation of clinical T(1a) renal tumors. *J Endourol*. Dec 2010;24(12):2017-2022. PMID 20932080
35. Castle SM, Salas N, Leveillee RJ. Initial experience using microwave ablation therapy for renal tumor treatment: 18-month follow-up. *Urology*. Apr 2011;77(4):792-797. PMID 21324512
36. Guan W, Bai J, Hu Z, et al. Retroperitoneoscopic microwave ablation of renal hamartoma: middle-term results. *J Huazhong Univ Sci Technol Med Sci*. Oct 2010;30(5):669-671. PMID 21063854
37. Keane MG, Bramis K, Pereira SP, et al. Systematic review of novel ablative methods in locally advanced pancreatic cancer. *World J Gastroenterol*. Mar 7 2014;20(9):2267-2278. PMID 24605026
38. Li X, Fan W, Zhang L, et al. CT-guided percutaneous microwave ablation of adrenal malignant carcinoma: Preliminary results. *Cancer*. Nov 15 2011;117(22):5182-5188. PMID 21523760
39. Pusceddu C, Sotgia B, Fele RM, et al. Treatment of bone metastases with microwave thermal ablation. *J Vasc Interv Radiol*. Feb 2013;24(2):229-233. PMID 23200605
40. Yu MA, Liang P, Yu XL, et al. Sonography-guided percutaneous microwave ablation of intrahepatic primary cholangiocarcinoma. *Eur J Radiol*. Nov 2011;80(2):548-552. PMID 21300500
41. Yue W, Wang S, Wang B, et al. Ultrasound guided percutaneous microwave ablation of benign thyroid nodules: safety and imaging follow-up in 222 patients. *Eur J Radiol*. Jan 2013;82(1):e11-16. PMID 22940229
42. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 2.2018. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf Accessed August 3, 2018.
43. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 2.2018. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf Accessed August 3, 2018.
44. National Institute for Health and Care Excellence (NICE). Microwave ablation for treating liver metastases [IPG553]. 2016; <https://www.nice.org.uk/guidance/ipg553> Accessed August 3, 2018.
45. National Institute for Health and Care Excellence (NICE). Microwave Ablation of Hepatocellular Carcinoma [IPG214]. 2007; <https://www.nice.org.uk/guidance/ipg214>. Accessed August 3, 2018.
46. Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. May 2013;143(5 Suppl):e278S-313S. PMID 23649443